Published in J Thromb Haemost on December 22, 2008
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ (2011) 1.96
Venous thromboembolism and cancer risk among elderly adults in the United States. Cancer Epidemiol Biomarkers Prev (2014) 0.86
Cancer begets venous thromboembolism, but is venous thromboembolism a risk factor for cancer? J Thromb Haemost (2009) 0.77
Hairy cell leukaemia and venous thromboembolism: a case report and review of the literature. Blood Transfus (2014) 0.75
Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism. PLoS One (2016) 0.75
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Travel and risk of venous thrombosis. Lancet (2000) 5.23
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med (2001) 3.07
Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med (1989) 2.73
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost (2010) 2.08
Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem (2001) 2.02
The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood (1986) 1.98
Deep-vein thrombosis. Lancet (1999) 1.98
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost (2003) 1.95
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther (2007) 1.95
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost (2009) 1.95
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
Probabilities of identity-by-descent patterns in sibships when the parents are not genotyped. Genet Epidemiol (1997) 1.81
A hierarchy of SSB protomers in replication protein A. Genes Dev (1996) 1.80
TDT with covariates and genomic screens with mod scores: their behavior on simulated data. Genet Epidemiol (1995) 1.77
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Very-high-energy gamma rays from a distant quasar: how transparent is the universe? Science (2008) 1.65
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost (2004) 1.63
IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol (1994) 1.62
Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost (2001) 1.58
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost (2006) 1.55
Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up. J Thromb Haemost (2009) 1.55
Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost (2007) 1.54
Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost (2003) 1.54
Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism--an overview. Thromb Haemost (2000) 1.51
Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost (2008) 1.51
False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal. J Thromb Haemost (2011) 1.45
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol (1992) 1.43
Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost (1996) 1.42
Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics. Intern Emerg Med (2007) 1.41
Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Ann Intern Med (1998) 1.41
Introducing a null mutation in the mouse K6alpha and K6beta genes reveals their essential structural role in the oral mucosa. J Cell Biol (2000) 1.41
Variable very-high-energy gamma-ray emission from the microquasar LS I +61 303. Science (2006) 1.40
The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica (1997) 1.39
Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. J Thromb Haemost (2008) 1.39
Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. Lupus (2005) 1.38
False positives and false negatives in genome scans. Adv Genet (2001) 1.38
Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost (2009) 1.35
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost (2009) 1.28
Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost (2006) 1.27
Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost (1997) 1.27
Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med (1993) 1.26
Use of high-performance liquid chromatography-tandem mass spectrometry to distinguish Panax ginseng C. A. Meyer (Asian ginseng) and Panax quinquefolius L. (North American ginseng). Anal Chem (2000) 1.23
Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost (1999) 1.23
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost (2013) 1.21
Multivariate and multilocus variance components method, based on structural relationships to assess quantitative trait linkage via SEGPATH. Genet Epidemiol (2003) 1.20
Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med (1994) 1.17
The nonhelical tail domain of keratin 14 promotes filament bundling and enhances the mechanical properties of keratin intermediate filaments in vitro. J Cell Biol (2001) 1.15
An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. J Vasc Surg (1999) 1.13
Chemical and biological characterization and clinical evaluation of botanical dietary supplements: a phase I red clover extract as a model. Curr Med Chem (2004) 1.12
Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood (1987) 1.12
Differential ethanol sensitivity of subpopulations of GABAA synapses onto rat hippocampal CA1 pyramidal neurons. J Neurophysiol (1997) 1.11
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost (2012) 1.10
Equine estrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol (2001) 1.09
Rapid eye movement sleep deprivation selectively impairs recall of fear extinction in hippocampus-independent tasks in rats. Neuroscience (2006) 1.08
Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovasc Dis (2006) 1.08
Neurotrophins in cell survival/death decisions. Adv Exp Med Biol (1999) 1.08
Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma (2011) 1.08
Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost (2005) 1.07
Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer (1998) 1.07
Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol (2005) 1.06
Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica (2001) 1.06
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg (1997) 1.06
Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost (2010) 1.04
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke (1995) 1.04
Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann Rheum Dis (1990) 1.03
A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost (2000) 1.03
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood (2000) 1.02
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol (2013) 1.01
Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis (2000) 1.01
Cancer and venous thromboembolism. Am Heart J (1996) 1.01
Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost (1992) 1.00
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther (2012) 1.00
The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood (1999) 1.00
The post-thrombotic syndrome. Curr Opin Pulm Med (2000) 0.98
Cortical spreading depression induces oxidative stress in the trigeminal nociceptive system. Neuroscience (2013) 0.97
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med (2013) 0.97
Testing causal hypotheses in multivariate linkage analysis of quantitative traits: general formulation and application to sibpair data. Genet Epidemiol (1998) 0.97
Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol (2006) 0.97
Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost (2000) 0.97